Diet approaches to help overweight women with endometrial cancer preserve fertility and lose weight
Official title: Three-Way Diet Comparison for Weight Loss in Overweight Endometrial Cancer Patients on Fertility-Sparing Regimens: A Randomized Controlled Trial
Run by Peking University People's Hospital · NCT07318727 · Data updated 2026-11-12
This study will see if intermittent fasting or a low-energy balanced diet help overweight or obese women with endometrial cancer lose weight and improve metabolic and tumor-related outcomes while they undergo fertility-preserving treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 81 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | January 10, 2025 |
| Main results expected | March 31, 2026 |
| Study ends | March 31, 2026 |
| Registry record updated | January 6, 2026 |
| Trial ID | NCT07318727 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women (≥18) with endometrial cancer or atypical hyperplasia, BMI ≥25 kg/m2, currently receiving fertility-preserving treatment and able to provide informed consent are eligible.
✕Probably not a fit
People with BMI <25, those not undergoing fertility-preserving therapy, pregnant women, or patients with the specified serious medical comorbidities are unlikely to benefit from these interventions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Overweight and obese women with endometrial cancer or atypical hyperplasia who are receiving fertility-preserving therapy are randomly assigned to one of three groups: a multi-professional guided '5+2' intermittent fasting program, a low-energy balanced diet, or routine self-managed care. The study collects body morphology and composition measures, glycolipid metabolism markers, molecular typing, and tumor outcomes during follow-up. Researchers will compare weight change, metabolic profiles, and tumor response across groups to determine the safety and effectiveness of the dietary approaches. The goal is to identify whether specific diet interventions can improve remission, metabolic health, and fertility outcomes in this population.
Why it matters
Potential benefit: If successful, these dietary programs could help reduce weight, improve metabolic health, and potentially support better tumor and fertility outcomes for overweight women preserving fertility.
How similar studies have gone: Retrospective and metabolic studies suggest intermittent fasting and low-energy diets can improve weight and glycolipid markers, but randomized data specifically in fertility-sparing endometrial cancer patients are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥18 years old * diagnosed as endometrial cancer or atypical hyperplasia * fertility-preserving therapy * BMI≥25 kg/m2 * informed consent. Exclusion Criteria: * those with communication barriers * pregnant women * medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.
Where it's running
-
Peking University People's Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Li Xiaodan, Master
- Email: lxd_2000_510@163.com
- Phone: 15010305099
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
National registry of endometrial cancer cases in Italy
This project will collect clinical and molecular information from adults treated for endometrial cancer at participating Italian oncology centers to see if a national database can improve understanding of outcomes and care.
-
IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7
This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.
-
Using AI to predict risks in endometrial cancer management
This study is testing if using artificial intelligence can help doctors better predict risks and improve treatment for women with endometrial cancer, especially to help preserve fertility in those with low-risk profiles.
-
Weight management for overweight endometrial cancer patients undergoing fertility-sparing treatment
This study tests if a weight management program can help overweight women with endometrial cancer who want to preserve their fertility feel better and improve their treatment results.
-
Testing VLS-1488 for advanced cancers
This study is testing a new oral medication called VLS-1488 to see if it is safe and effective for people with advanced solid tumors.
-
Pembrolizumab plus Ataluren for metastatic colorectal or endometrial cancer with mismatch repair changes
This trial will try the combination of pembrolizumab and ataluren in adults with metastatic colorectal cancer (with or without mismatch repair deficiency) or metastatic mismatch-repair-deficient endometrial cancer to see if the treatment is safe and helps shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.